tiprankstipranks
Advertisement
Advertisement

DE:1CG Stock Latest News

Crispr Therapeutics durability data ‘encouraging,’ says Morgan Stanley
The FlyCrispr Therapeutics durability data ‘encouraging,’ says Morgan Stanley
9d ago
CRSP
Crispr Therapeutics price target raised to $55 from $48 at Goldman Sachs
PremiumThe Fly
Crispr Therapeutics price target raised to $55 from $48 at Goldman Sachs
30d ago
CRSP
Crispr Therapeutics price target lowered to $82 from $83 at BofA
PremiumThe Fly
Crispr Therapeutics price target lowered to $82 from $83 at BofA
1M ago
CRSP
Crispr Therapeutics price target raised to $55 from $48 at Goldman Sachs
PremiumThe Fly
Crispr Therapeutics price target raised to $55 from $48 at Goldman Sachs
1M ago
CRSP
CRISPR Therapeutics: Buy Rating Reiterated, $80 Price Target Maintained Ahead of Key HORIZON Catalyst
PremiumRatings
CRISPR Therapeutics: Buy Rating Reiterated, $80 Price Target Maintained Ahead of Key HORIZON Catalyst
1M ago
CRSP
Analyst Maintains Buy on CRISPR Therapeutics as Casgevy Ramp and Diversified Pipeline Strengthen Long-Term Growth Outlook
PremiumRatingsAnalyst Maintains Buy on CRISPR Therapeutics as Casgevy Ramp and Diversified Pipeline Strengthen Long-Term Growth Outlook
1M ago
CRSP
Crispr Therapeutics: Strong Casgevy Uptake, Expanding Pipeline and Cash Runway Support Unchanged $82 Price Target and Buy Rating
Premium
Ratings
Crispr Therapeutics: Strong Casgevy Uptake, Expanding Pipeline and Cash Runway Support Unchanged $82 Price Target and Buy Rating
1M ago
CRSP
Casgevy Momentum and Pipeline Catalysts Drive Yigal Nochomovitz to Maintain Buy Rating and Raise Price Target to $88
Premium
Ratings
Casgevy Momentum and Pipeline Catalysts Drive Yigal Nochomovitz to Maintain Buy Rating and Raise Price Target to $88
1M ago
CRSP
Citi ups Crispr Therapeutics target on Casgvey momentum
PremiumThe Fly
Citi ups Crispr Therapeutics target on Casgvey momentum
1M ago
CRSP
Crispr Therapeutics price target raised to $88 from $82 at Citi
PremiumThe Fly
Crispr Therapeutics price target raised to $88 from $82 at Citi
1M ago
CRSP
Crispr Therapeutics reports Q2 EPS (94c), consensus ($1.18)
PremiumThe Fly
Crispr Therapeutics reports Q2 EPS (94c), consensus ($1.18)
1M ago
CRSP
Crispr Therapeutics AG Slides Despite Bullish Wall Street
PremiumWeekend Updates
Crispr Therapeutics AG Slides Despite Bullish Wall Street
2M ago
CRSP
CRISPR Therapeutics: Buy Rating Reiterated as Pediatric CASGEVY Label Expands; $80 Price Target Maintained
PremiumRatingsCRISPR Therapeutics: Buy Rating Reiterated as Pediatric CASGEVY Label Expands; $80 Price Target Maintained
2M ago
CRSP
Gil Blum Reiterates Buy on CRISPR Therapeutics, Maintains $82 Price Target on Pipeline Upside and 2026 Data Catalysts
Premium
Ratings
Gil Blum Reiterates Buy on CRISPR Therapeutics, Maintains $82 Price Target on Pipeline Upside and 2026 Data Catalysts
2M ago
CRSP
Private Markets: Bezos’ Prometheus raises $12B as OpenAI files for IPO
Premium
The Fly
Private Markets: Bezos’ Prometheus raises $12B as OpenAI files for IPO
3M ago
GS
TP
Crispr Therapeutics assumed at Equal Weight from Underweight at Morgan Stanley
PremiumThe Fly
Crispr Therapeutics assumed at Equal Weight from Underweight at Morgan Stanley
3M ago
CRSP
Shareholders Approve New Incentive Plan and Governance Measures
PremiumCompany Announcements
Shareholders Approve New Incentive Plan and Governance Measures
3M ago
8K
CRSP
FDA issues draft guidance to help accelerated cell, gene therapies for patients
PremiumThe Fly
FDA issues draft guidance to help accelerated cell, gene therapies for patients
3M ago
AZN
BMY
Crispr Therapeutics price target raised to $56 from $50 at Bernstein
PremiumThe Fly
Crispr Therapeutics price target raised to $56 from $50 at Bernstein
4M ago
CRSP
FDA Commissioner Marty Makary resigns
PremiumThe FlyFDA Commissioner Marty Makary resigns
4M ago
AZN
BMY
Crispr Therapeutics price target raised to $76 from $74 at Evercore ISI
Premium
The Fly
Crispr Therapeutics price target raised to $76 from $74 at Evercore ISI
4M ago
CRSP
Crispr Therapeutics price target raised to $82 from $80 at Citi
Premium
The Fly
Crispr Therapeutics price target raised to $82 from $80 at Citi
4M ago
CRSP

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >